Peptides for Athletes: What Is Banned, What Is Not, and Who Can Use Them

The 2026 wording, for anyone checking against their federation's adopted version: S2.2.4 names CJC-1295, sermorelin, tesamorelin, ipamorelin and hexarelin; S2.3 names IGF-1 "and its analogues" and "Thymosin-ß4 and its derivatives e.g. TB-500"; S2.2.3 names AOD-9604 among growth hormone fragments, which matters for the PHYSIQ and SHRED blends; S4.4.1 names MOTS-c among AMPK activators; kisspeptin sits under S2.2.1. M2.2 prohibits intravenous infusions or injections of more than 100 mL in any 12-hour period outside hospital treatment, surgery or diagnostic investigation, which a subcutaneous injection is not but an IV NAD+ or glutathione drip may be. The List marks S0 substances "Specified" and S2 "non-Specified"; that governs how a case is handled after a positive sample, not whether the substance is prohibited.

Under the Code an athlete is responsible for any prohibited substance found in their sample, and intent is not required for a violation. A prescription does not change that, because the prescription is not the problem; the presence of the substance is. Detection methods are published and keep improving: Drug Testing and Analysis carried a 2017 paper on the detection and metabolism of confiscated BPC 157 and a 2012 paper characterizing the thymosin beta-4 fragment in TB-500 because of its doping potential, and a 2019 paper in Rapid Communications in Mass Spectrometry described a plasma method for MOTS-c built for doping control. Samples are stored for years for reanalysis.

A therapeutic use exemption is granted for a documented medical need treated with an appropriate medication, and a compounded non-approved substance used for an injury is not an easy case to make. USADA's own BPC-157 guidance says a TUE for it is unlikely to be approved because permitted alternatives exist, while noting each application is considered case by case. The same logic applies with more force to TB-500 and the growth-hormone secretagogues, where permitted alternatives for a tendon injury or poor sleep are numerous.

The NCAA, professional leagues, some military roles and some employers maintain their own lists that do not match WADA's. The NCAA's banned classes include "Peptide hormones, growth factors, related substances and mimetics," and its published examples for that class name BPC-157 and TB-500 directly, alongside growth hormone, IGF-1 and ibutamoren. It also bans any substance chemically or pharmacologically related to a banned class whether or not it is listed, and holds the student-athlete accountable regardless. A college athlete should treat this page's answer as identical to the WADA answer.

Is BPC-157 banned and do peptides show up on a drug test go into this further.

If you compete under any testing programme, stop here. Nothing below changes that answer.

Tendons and ligaments are sparsely vascularized compared with muscle, which is much of why a strained hamstring resolves in weeks and an Achilles tendinopathy can drag on for a year. Healing depends on cells arriving at the injury, new vessels forming to supply them, and collagen being laid down and remodeled under load. The animal work on BPC-157 and TB-500 is about exactly those steps.

The first days after a soft-tissue injury are inflammatory by design; that is how repair cells are recruited. The problem is inflammation that does not resolve, or is re-triggered by training through the injury. Heavy NSAID use to push through it has its own cost, and the gastrointestinal literature on BPC-157, where the compound was first studied, is largely about protection of the gut lining against NSAID and alcohol injury in animal models.

Most adult growth hormone is released in pulses during slow-wave sleep, and a 2000 paper in JAMA reported that in healthy men slow-wave sleep and growth hormone secretion decline together across adulthood. An athlete sleeping badly in a heavy block is losing recovery on two fronts, which is why the secretagogues, prescribed to prompt the pituitary's own pulse, are described by patients most consistently in terms of sleep depth.

Between-session fatigue that does not respond to more sleep and food is sometimes a mitochondrial signaling problem rather than a fuel problem. MOTS-c speaks to that: a 2021 paper in Nature Communications reported plasma MOTS-c rising after acute exercise in humans, and action on age-dependent physical decline in mice. The human part is observational; the intervention part is in animals.

BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice. Animal and cell work describes it activating the VEGFR2 receptor and angiogenic signaling (Journal of Molecular Medicine, 2017), increasing growth-hormone receptor expression in cultured tendon fibroblasts (Molecules, 2014), and promoting tendon fibroblast outgrowth, survival and migration (Journal of Applied Physiology, 2011). Rat studies in the Journal of Orthopaedic Research on transected Achilles tendon (2003), Achilles detachment (2006) and transected quadriceps (2006), and on crush injury in Surgery Today (2008), report faster functional recovery in treated animals. The gastrointestinal literature, reviewed in Current Pharmaceutical Design in 2011 and 2018, is the largest body of work on the compound.

There are no randomized controlled trials of BPC-157 in humans for tendon, ligament or muscle injury; early-phase human work exists for inflammatory bowel indications. The honest framing is "described in preclinical research and used clinically," not "proven in people."

On its own, BPC-157 suits the athlete whose main problem is the gut: stomach pain from a heavy NSAID habit, or the gastrointestinal upset of high-volume endurance training. For a tendon or ligament injury it is more often prescribed in the stack below. Product page: BPC-157, priced at /cost/bpc-157.

TB-500 is a synthetic fragment of thymosin beta-4, the body's main actin-sequestering protein. Actin is what lets a cell move, and the research describes thymosin beta-4 acting on cell migration, angiogenesis and wound repair through that route (Trends in Molecular Medicine, 2005), with animal work on dermal wound healing (Journal of Investigative Dermatology, 1999) and cardiac repair in mice (Nature, 2004). A 2021 paper in the American Journal of Physiology – Cell Physiology identified thymosin beta-4 as a human exerkine, released into the circulation with exercise, which is part of why it draws athletes' attention.

The human data is thinner than the marketing suggests: a randomized, placebo-controlled safety and pharmacokinetic study of intravenous full-length thymosin beta-4 in healthy volunteers (Annals of the New York Academy of Sciences, 2010) and a phase 2 randomized trial of thymosin beta-4 eye drops in severe dry eye (Cornea, 2015). There are no randomized controlled trials of TB-500 in humans for musculoskeletal injury.

The pairing exists because the two are described as acting on different steps: BPC-157 on vessel formation and cell responsiveness, TB-500 on cell motility. A 2026 paper in Joint Diseases and Related Surgery examined the two alone and together in a rat Achilles tendon model with histopathological and biomechanical endpoints, the first study to look at the combination directly. For a tendon, ligament or muscle injury in an untested athlete, the BPC-157 + TB-500 stack is the usual starting prescription; peptides for tendon and ligament injuries covers the injury side in more depth.

KLOW adds GHK-Cu and KPV to BPC-157 and TB-500. GHK-Cu is a copper-binding tripeptide found in human plasma; the research describes it stimulating collagen synthesis in cultured fibroblasts (FEBS Letters, 1988), modulating matrix metalloproteinases in wounds (Journal of Investigative Dermatology, 1999) and, in a 2015 review in BioMed Research International, acting on multiple tissue-remodeling pathways. It has human data in skin, including topical treatment of diabetic ulcers (Wound Repair and Regeneration, 1994). KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone; a 2008 paper in Gastroenterology described its uptake by the PepT1 transporter and reduction of intestinal inflammation, and a 2008 review in Endocrine Reviews covers the anti-inflammatory biology of the melanocortin tripeptides.

KLOW suits the athlete whose injury comes with joint pain and stiffness rather than a single tendon that hurts on loading. Neither addition has human trial evidence in joints. Product page: KLOW.

REVIVE pairs GHK-Cu and a small amount of TB-500 with CJC-1295 and ipamorelin. It is aimed at the athlete who is not injured but is not recovering: the secretagogue pair covers the sleep and growth-hormone side, the repair peptides cover connective tissue. The evidence statement is the same as for its components: preclinical for GHK-Cu and TB-500 in this use, human pharmacology but no athletic outcome trials for CJC-1295 and ipamorelin. Product page: REVIVE.

SERENITY combines DSIP and Selank with CJC-1295 and ipamorelin. DSIP has the oldest human literature in this category: a 1981 paper in the Lancet reported that synthetic DSIP improved sleep in insomniacs, followed by double-blind work in chronic insomnia (Neuropsychobiology, 1992) and a 2006 review in the Journal of Neurochemistry titled "a still unresolved riddle." Selank is a tuftsin-analog heptapeptide with Russian clinical work in generalized anxiety disorder, including a 2014 comparison with phenazepam; a 2021 review in the Journal of Clinical Pharmacology places it among agents acting on GABA signaling.

SERENITY suits the athlete whose recovery problem is sleep quality inside a heavy block, particularly where pre-sleep anxiety is part of it. None of that work was done in athletes, and the DSIP trials are small and decades old. Product page: SERENITY.

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. The 2015 Cell Metabolism paper that characterized it reported action on AMPK signaling and metabolic homeostasis in mice, and a 2018 paper in the same journal described it translocating to the nucleus under metabolic stress. Human data is observational: plasma MOTS-c is reported lower in people with diabetes (Frontiers in Endocrinology, 2019), associated with insulin sensitivity in lean but not obese individuals (Journal of Investigative Medicine, 2018), and higher after exercise (Nature Communications, 2021). There are no randomized human trials of MOTS-c for any outcome.

For the untested athlete MOTS-c is prescribed for flat energy and slow between-session recovery once sleep, calories and iron have been checked. For the tested athlete it is now named on the List under S4.4.1, so the earlier ambiguity no longer exists. Product page: MOTS-c.

Sermorelin, CJC-1295 and tesamorelin bind the GHRH receptor and prompt a pulse of your own growth hormone. Ipamorelin acts through the ghrelin receptor instead, which is why the two are paired: two signals converging on one pulse. Because the pituitary does the releasing, normal feedback regulation stays in place.

This is the sub-category with the most human pharmacology. CJC-1295 was studied in healthy adults in the Journal of Clinical Endocrinology and Metabolism in 2006, which reported prolonged growth hormone and IGF-1 secretion after single doses, with a companion paper reporting that pulsatile secretion persisted. Ipamorelin was characterized as the first selective growth hormone secretagogue in the European Journal of Endocrinology in 1998, with human pharmacokinetic modeling in Pharmaceutical Research in 1999. Sermorelin has randomized human data from the 1990s in older adults, including a 1997 paper in the Journal of Clinical Endocrinology and Metabolism on long-term administration. Tesamorelin is the exception in the whole category: it is the active ingredient of an FDA-approved product, on the strength of phase 3 randomized placebo-controlled trials in HIV-associated abdominal fat accumulation (New England Journal of Medicine, 2007; Journal of Clinical Endocrinology and Metabolism, 2010).

What this class does not have is human trial evidence for athletic performance, and the approved tesamorelin indication is a different population with a different goal. Patients most consistently describe changes in sleep depth rather than in the mirror. Peptides vs HGH explains why this is a different proposition from injecting growth hormone, and peptides for muscle growth and recovery covers the body-composition question. Product pages: CJC-1295 / Ipamorelin, sermorelin, tesamorelin.

A modified form of insulin-like growth factor 1 engineered to bind IGF binding proteins poorly and therefore stay active longer (Journal of Molecular Endocrinology, 1992), acting at the IGF-1 receptor to drive anabolic signaling directly. Localized IGF-1 infusion produced skeletal muscle hypertrophy in rats (Journal of Applied Physiology, 1998), and the LR3 variant was anabolic in dexamethasone-treated rats (Biochemical Journal, 1992). It is the compound where the growth-signaling cautions matter most: a 2004 systematic review in the Lancet examined circulating IGF-1 and cancer risk, and a 1987 paper in the New England Journal of Medicine documented IGF-1's short-term metabolic effects, including on glucose, in healthy adults.

There are no human trials of IGF-1 LR3 for any indication, it is prohibited under S2, and it is not a casual prescription. A physician will want a reason that is not "I want to be bigger." Product page: IGF-1 LR3.

On 15 April 2026, twelve peptides were removed from 503A Category 2 after their nominators withdrew the nominations, among them BPC-157, TB-500, MOTS-c, KPV, DSIP (emideltide), Semax, Epitalon and injectable GHK-Cu. The FDA's own safety-risk page, current as of 22 April 2026, now lists those, plus CJC-1295 and ipamorelin acetate on the 503A side, under "bulk drug substances nominated but withdrawn" rather than in the active Category 2 table. As of the 14 May 2026 update, 503A Category 2 holds six substances, none a peptide on this page.

Removal from Category 2 is not placement in Category 1, and none of the peptides on this page currently appears in Category 1. What it does mean is that the "flagged for significant safety risk" description that dominated 2023–2025 coverage no longer applies.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee discussed BPC-157, KPV, TB-500 and MOTS-c, each in free base and acetate forms, for inclusion on the 503A Bulks List; on 24 July it discussed emideltide (DSIP), Semax and Epitalon. The committee voted to recommend adding BPC-157, KPV and TB-500, each by eight votes to six with one abstention, and MOTS-c by seven to five with two abstentions. On the second day it voted against emideltide, six to seven with one abstention, and recommended Epitalon and Semax.

Those are recommendations, not final decisions. The FDA issues its own determination after weighing the vote, public comment and its scientific review, and formal addition to the 503A Bulks List goes through rulemaking; that determination is pending. A further meeting before the end of February 2027 is scheduled to consider GHK-Cu, Dihexa acetate, LL-37, PEG-MGF and Melanotan II. GHK-Cu for non-injectable routes was returned to Category 1 on 14 May 2026 after one nominator clarified it had only meant to withdraw the injectable route.

So for the products in the short-answer table built on BPC-157, TB-500, KPV and MOTS-c, the accurate description today is: no longer in Category 2, formally recommended for the positive list by the advisory committee, awaiting final FDA action. For DSIP, in SERENITY, the committee's recommendation went the other way, and that too awaits FDA action.

CJC-1295 and ipamorelin acetate were not on the July agenda; both now appear on the FDA's withdrawn list on the 503A side rather than in active Category 2. Sermorelin was the active ingredient of Geref, approved on 28 December 1990 and later discontinued, with a Federal Register determination that it was not withdrawn for safety or effectiveness reasons. Tesamorelin is the active ingredient of Egrifta, approved on 10 November 2010 for a specific HIV-related indication; compounded tesamorelin is not that product. IGF-1 LR3 has never been an approved drug and does not appear on the FDA's 503A category lists as of the 14 May 2026 update.

For BPC-157, the stack and KLOW, what is described in the first two weeks is background inflammation settling rather than the injury itself changing; some athletes notice nothing in that window, which is normal. Weeks two to six are where tissue-level change would be expected if it occurs, based on the animal timelines. A vial is sized at about four weeks of once-daily dosing and refills run on 28-day cycles, which is why prescribers frame progress in four-week windows. Chronic tendinopathy is generally described as slower than a recent acute injury.

For REVIVE, SERENITY and the secretagogues on their own, the change most consistently described is in sleep depth, often within the first couple of weeks. Anything beyond that is slower and less consistent, and IGF-1 on bloodwork gives a physician a better read on the axis than the mirror does.

Prescribers describe between-session energy as what MOTS-c patients report, and describe it as gradual; no human trial puts a number on it. Across the category, treatment is long-term on 28-day refills, the physician decides whether it continues, and no withdrawal or rebound is described in the literature for any compound on this page.